The highlighted four-component series in THE BRAND NEW York Times, this week targets the significance of B-RAF mutations and another generation of tumor therapies. ‘We congratulate Plexxikon and Roche on the dramatic achievement of their substance PLX-4032, a novel treatment for melanoma and additional cancers harboring the V600E mutation of the B-RAF kinase gene,’ stated Robert Cole, M.D., Chief Medical Officer at AutoGenomics. Melanoma may be the most serious kind of skin tumor with about 70,000 new melanoma situations diagnosed every year in america and about 160,000 world-wide.Supporters insist that colleges could serve the same foods, just switch to trans-fat-free shortening and oils. The bill would need no noticeable changes to school kitchens or how food is prepared. Colorado’s best-known school nutritionist says the complete trans-fats ban is perform-able. Ann Cooper, author of the ‘Renegade Lunch Lady’ blog, manages food assistance at the Boulder Valley district, thought to be the only public college district in the constant state that’s trans-fat free. ‘We don’t serve convenience meals, we don’t serve processed foods,’ Cooper said. ‘That is where the trans-extra fat is. You make from scratch, it isn’t a issue cutting all of the trans-fat.’.
Earlier this summer, the results of the TORPEDO trial were released. And while we are very interested in whether or not “percutaneous interventions to remove thrombi in the popliteal, femoral, or iliac veins, when performed in conjunction with anticoagulant therapy is normally [sic] much better than anticoagulant therapy only in preventing recurrent venous thromboembolism”, what we really want to know is: why is it known as the TORPEDO study? In this full case, it means “Thrombus Obliteration by Quick Percutaneous Endovenous Intervention in Deep Venous Occlusion”, and if you browse the database of scientific trials maintained by the government, there’s plenty of other amusing acronyms to be had.